For example, in skin, lung, liver, systemic sclerosis and renal fibrosis models, the PDGFR inhibitor (imatinib) could inhibit fibroblast activation, reduce ECM synthesis, prevent fibrosis formation and improve the formed fibrosis [12]. The gene discussed is PDGFRB; the disease is renal fibrosis.